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Summary
Objective: To assess the resources available in the provision of epilepsy care across 
Europe and the developments since the International League Against Epilepsy 
(ILAE) survey published in 2003 (data collected in 2000).
Methods: An updated online version of the European Epilepsy Services Inventory 
was distributed to all European chapters of the ILAE (N = 47) and responses were 
obtained from 33 chapters (response rate 70%). To assess trends and allow compari-
sons with the survey published in 2003, the responding countries were divided into 4 
groups (Western, Central, Southern, and Eastern). Responses from European Union 
(EU) member states are reported as a subgroup (N = 23), since the current survey is 
a part of the EU- funded European Study on the Burden and Care of Epilepsy 
(ESBACE, www.esbace.eu).
Results: The total number of physicians involved in epilepsy care had increased 
since 2000, with the largest increase seen for neurologists. The gap between the best- 
and the least- provided areas with regard to the competence of the providers had di-
minished. However, the density of comprehensive multidisciplinary epilepsy teams 
had not changed to any greater degree. The main problems reported by the chapters 
were to a large extent the same as in 2000 and included lack of specialists and spe-
cialist care, lack or underuse of epilepsy surgery, and problems regarding financing 
and resource allocation. Several chapters also highlighted problems with healthcare 
structure and organization.
Significance: Although there have been some improvements concerning the availa-
bility of care for people with epilepsy in Europe over the last 17 years, there are still 
a number of problem areas with little improvement or where there are important re-
gional differences.
K E Y W O R D S
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1 |  INTRODUCTION
The Commission of European Affairs (CEA) of the 
International League Against Epilepsy (ILAE) performed 
a survey of the provision of epilepsy care in Europe, which 
was published in 2003 (data collected in 2000).1 The study 
assessed the needs and resources available in the provision 
of basic epilepsy care across Europe by use of a structured 
inventory, the European Epilepsy Services Inventory (EESI). 
The 2000 survey revealed differences between and within 
countries and shortage of resources for the provision of 
epilepsy care. The ongoing EU- funded European Study on 
the Burden and Care of Epilepsy (ESBACE, www.esbace.
eu) aims among other things to provide data on the current 
provision of epilepsy care in Europe, with emphasis on the 
European Union (EU) member states. One of the objectives 
was therefore to repeat the 2000 inventory to assess the cur-
rent situation as well as to describe in what ways the pro-
vision of epilepsy care in Europe has changed over the last 
17 years. Herein we report the findings of the repeat survey, 
with subgroup analyses of participating chapters from EU 
member states.
2 |  MATERIAL AND METHODS
2.1 | European Epilepsy Services Inventory
The EESI questionnaire from the 2000 survey,1 updated 
with current antiepileptic drugs (AEDs) and questions re-
garding the availability of registers of relevance for moni-
toring epilepsy care, was converted to an online form. The 
EESI contains 2 parts. The first part collects data on popu-
lation size, number of physicians within different medical 
specialties, registered AEDs, and the economic availability 
of epilepsy care (reimbursements of visits and investiga-
tions). The second part of the EESI is more descriptive 
and asks responding chapters to assess which medical 
specialties of practitioners provide basic epilepsy care for 
different patient categories (children, adults, elderly, and 
learning disabled) in the best- and least- provided areas of 
the country, respectively. Categorization of the best- or 
least- provided areas was left to the discretion of the re-
sponding chapters. In addition, chapters were asked in an 
open- ended manner to describe obstacles to the provision 
of basic epilepsy care.
2.2 | Survey and analysis
Invitations were sent to all European chapters of the ILAE in 
October 2016, with reminders to nonresponders sent repeat-
edly (in total, 117 reminders were sent in 5 rounds) until June 
2017. Twelve of the 14 nonresponders were from the Eastern 
group and 2 were from the Western group. Responses were 
submitted by chapter board members, often the president. 
Data were analyzed using descriptive statistics and are pre-
sented at a group level. Participating countries were catego-
rized into regions (Western, Southern, Eastern, and Central) 
according to the 2000 survey (new countries were catego-
rized according to geographic location; see Table S1 for 
grouping). Because of the ESBACE objectives on the provi-
sion of epilepsy care in the EU, data are presented both for all 
ILAE European chapters and for the subgroup of EU member 
states.
3 |  RESULTS
3.1 | Response rate and number of 
physicians
In total, 33 ILAE chapters responded (including 23 of 28 
EU countries; Table 1). The number of physicians, neurolo-
gists, neuropediatricians, and other specialists involved in 
the treatment of epilepsy are presented in Table 2. There 
were considerable differences in the density of neurologists 
between countries. Within the EU, the reported number of 
neurologists per million inhabitants in each group was a me-
dian of (min- max): Western, 59 (12- 81); Eastern, 109 (47- 
125); Southern, 49 (31- 111); and Central, 102 (81- 119). If 
countries outside the EU were included, there was more vari-
ability between countries in the Eastern region: Western, 63 
(12- 81); Eastern, 119 (20- 299); Southern, 49 (31- 111); and 
Central, 82 (81- 119).
Compared to the survey conducted in 2000 and consid-
ering only the 26 countries responding to both surveys, the 
median number of practitioners was higher for all inves-
tigated medical specialties, with the exception of pediatric 
Key Points
• The provision of epilepsy care was assessed in a 
survey of 33 European countries and compared to 
a similar survey 17 years ago
• There was an increase in the number of physicians 
involved in epilepsy care
• The gap between the least- and the best-provided 
areas was diminished
• More persons with epilepsy and learning disabili-
ties were managed by neurologists
• The density of multidisciplinary epilepsy teams 
had not increased much
• There were still a few countries lacking epilepsy 
surgery programs
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neurologists, for which the median number was unchanged 
between the surveys (Figure S1).
3.2 | Antiepileptic drug availability
The availability of AEDs is outlined in Table S3. 
Carbamazepine, clonazepam, diazepam, lamotrigine, and 
levetiracetam were registered in all responding countries. 
In addition to these drugs, gabapentin was registered in all 
responding EU countries. Systems for reimbursement of drug 
costs are diverse, but free AEDs were reported most com-
monly by countries in the Southern (6/7) and Central (3/4) 
groups, and more seldom by countries in the Western (7/11) 
or Eastern groups (5/10). A similar pattern was seen if only 
EU countries were considered (Table 3). The remaining 
countries, within or outside the EU, reported that AEDs were 
associated with patient fees. No countries reported a total ab-
sence of financial support.
3.3 | Economic availability of epilepsy care
As illustrated in Table 3, outpatient visits, hospitalizations, 
and investigations associated with epilepsy (neuroimaging, 
electroencephalography [EEG], and therapeutic drug moni-
toring [TDM]) were free for patients in all responding coun-
tries belonging to the Central group. All other groups had 
countries reporting patient fees. For EU countries, investiga-
tions such as neuroimaging, EEG, and TDM were also free for 
the patients in all countries belonging to the Western group.
3.4 | Provisions of basic epilepsy care
Responding countries were asked which specialties most 
often provided basic epilepsy care in the best- and the least- 
provided areas of the country for adults, children, elderly, 
and learning disabled (Table 4). Several categories of phy-
sicians could be considered for each choice. Neurologists 
often provided for adults in the best- provided areas in 97% 
of responding countries (96% in EU countries), for elderly 
in 87% (83% in EU countries), and for the learning disabled 
in 81% (83%). In the least- provided areas, neurologists often 
provided for adults in 93% of responding countries (100% in 
T A B L E  1  Responding ILAE Chapters per geographic group 
Albania Latvia
Austria Lithuania
Belgium Malta
Croatia Norway
Cyprus Poland
Czech Republic Portugal
Denmark Republic of Moldova
Estonia Romania
Finland Russia
France Serbia
Georgia Slovenia
Germany Sweden
Greece Switzerland
Hungary Turkey
Ireland Ukraine
Italy United Kingdom
Kazakhstan
n = 33, EU countries in gray = 23.
ILAE, International League Against Epilepsy.
T A B L E  2  Number of physicians and certain specialists per million inhabitants 
All European ILAE chapters EU
n Median Min Max n Median Min Max
Total number of physicians 32 4280 1794 6517 23 4303 2218 6362
Speciality
Neurologists 33 79 12 299 23 79 12 125
Neurosurgeons 32 16 5 39 22 15 5 39
Clinical neurophysiologists 15 5 1 68 8 6 2 15
Pediatricians 32 185 58 948 23 173 76 536
Pediatric neurologists 28 8 1 64 20 6 1 54
Psychiatrists 32 126 25 432 23 146 62 220
Child psychiatrists 30 16 2 77 21 17 2 47
General practitioners 32 636 65 1679 23 679 223 1679
Internists 30 304 35 1258 21 312 35 786
Geriatricians 22 14 1 72 15 19 2 72
n, number of reporting ILAE chapters.
ILAE, International League Against Epilepsy.
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EU countries), for elderly in 77% of the countries (77% in 
EU countries), and for patients with learning disorders in 60% 
(73% in EU countries). Pediatric neurologists often provided 
epilepsy care for children in the best- provided areas in 93% of 
responding countries (100% in EU countries) and in the least- 
provided areas in 68% of all chapters (75% in EU countries).
3.5 | Multidiciplinary epilepsy teams
The density of epilepsy teams is illustrated in Figure 1 (see 
Table S2 for details). All countries in the Western group re-
ported existence of teams with epilepsy surgery programs, 
whereas the Central, Southern, and Eastern groups had at least 
one responding country without such a program (overall 21%, 
EU countries 13%). The regional density of multidisciplinary 
teams with epilepsy surgery programs was one team per 9 mil-
lion inhabitants for all ILAE chapters (range, no team to one 
team per one million inhabitants), and one team per 5.48 mil-
lion inhabitants for EU countries (range, no team to one team 
per one million inhabitants). The regional density of multidis-
ciplinary teams without epilepsy surgery programs was one 
team per 3.94 million inhabitants for all ILAE chapters (range, 
no team to one team per 0.2 million inhabitants), and one team 
per 2.98 million inhabitants for EU- countries (range, no team 
to one team per 0.45 million inhabitants). Six of 33 countries 
(18%) reported no comprehensive multidisciplinary teams 
at all, including 5 of 23 EU countries (22%). The Southern, 
Central, and Eastern groups all contained at least one country 
reporting the absence of multidisciplinary teams with surgery 
programs, whereas all countries in the Western group reported 
existence of such teams. If only the 26 of 33 chapters that re-
sponded also to the 2000 inventory were considered, no clear 
differences in density of multidisciplinary teams with and 
without surgery programs could be seen1; the highest regional 
density in the present survey was 0.97 surgery teams per one 
million inhabitants (0.8 in 2000) and 4.4 nonsurgery teams per 
million inhabitants (5.3 in 2000).
3.6 | Registers
The updated EESI also assessed the availability of registers 
of value for monitoring epilepsy care, which was not done in 
T A B L E  3  Patient costs for epilepsy care in responding countries
All countries
Public (free of charge) Partly free (patient fees) No financial support
Group W S C E Total W S C E Total W S C E Total
No. responses 11 7 4 10 32 11 7 4 10 32 11 7 4 10 32
Outpatient visits 7 5 4 7 23 4 2 0 3 9 0 0 0 0 0
Hospitalizations 7 7 4 8 26 4 0 0 2 6 0 0 0 0 0
Antiepileptic drugs 7 6 3 5 21 4 1 1 5 11 0 0 0 0 0
Investigations
Neuroradiology 10 5 4 5 24 1 2 0 5 8 0 0 0 0 0
EEG 10 5 4 6 25 1 2 0 4 7 0 0 0 0 0
Blood chemistry 10 5 4 7 26 1 2 0 3 6 0 0 0 0 0
TDM 10 5 4 5 24 1 2 0 3 6 0 0 0 2 2
EU
Group W S C E Total W S C E Total W S C E Total
No. responses 9 5 4 5 23 9 5 4 5 23 9 5 4 5 23
Outpatient visits 6 3 4 4 17 3 2 0 1 6 0 0 0 0 0
Hospitalizations 6 5 4 4 19 3 0 0 1 4 0 0 0 0 0
Antiepileptic drugs 6 4 3 3 16 3 1 1 2 7 0 0 0 0 0
Investigations
Neuroradiology 9 3 4 3 19 0 2 0 2 4 0 0 0 0 0
EEG 9 3 4 3 19 0 2 0 2 4 0 0 0 0 0
Blood chemistry 9 3 4 4 20 0 2 0 1 3 0 0 0 0 0
TDM 9 3 4 3 19 0 2 0 2 4 0 0 0 0 0
W, Western; S, Southern; C, Central; E, Eastern; EEG, electroencephalography; TDM, therapeutic drug monitoring. The table shows in how many countries patients are 
required partly or completely to pay fees for certain aspects of their epilepsy care.
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2000. Existence of an International Classification of Diseases 
(ICD)–based register of patient visits was reported by 73% 
of all ILAE chapters (70% of chapters within in the EU), a 
drug database was reported by 70% of all ILAE chapters (74% 
within EU), and other registers of relevance for epilepsy care 
were reported by 30% of ILAE chapters and 26% of EU chap-
ters. Chapters belonging to the Western group most frequently 
reported the existence of other registers of value for the moni-
toring of epilepsy care, for instance, national quality registers.
3.7 | Problems in the provision of care
Responding chapters were asked to list the main obstacles to 
the provision of epilepsy care. Problems regarding financing 
and resource allocation were reported as most important by 
7 chapters (4 EU chapters), lack of specialists and special-
ist care was reported as most important by 6 chapters (5 EU 
chapters), and lack or underuse of epilepsy surgery was re-
ported as most important by 5 chapters (3 EU chapters). Also 
reported as most important was lack of comprehensive care 
(4 chapters, 3 EU chapters), insufficient professional educa-
tion or expertise (4 chapters, 3 EU chapters), high costs of 
AEDs (4 chapters, 1 EU chapter), and stigma or social prob-
lems (3 chapters, 2 EU chapters). Other problems mentioned 
concerned healthcare structure and organization and included 
lack of structural quality criteria, lack of formal standards for 
care, lack of follow- up from the National Board of Health 
and Welfare, delays and gaps in care pathways, and lack of 
epidemiologic surveillance.
4 |  DISCUSSION
Herein we report the results of a pan- European inventory of 
epilepsy care. The European Epilepsy Services Inventory (or 
EESI) concentrates on the prerequisites for and the provi-
sion of basic epilepsy care. The results give several impor-
tant insights into the current state of basic epilepsy care in 
Europe and the challenges faced by its providers. There are 
few reports on the provision of epilepsy care in Europe. In 
the United Kingdom, there had been little improvement in the 
provision of epilepsy care between 2009 and 2012,2 a finding 
that is in line with our results.
By re- use of the previously developed EESI form, our 
findings can be compared to data from 2000, and therefore 
at least to some extent allow reflections on the development 
of epilepsy care in Europe over the last 17 years. It must be 
remembered, however, that the European countries respond-
ing to the survey were not identical between the first and the 
second survey. Of the 33 answering countries in 2017, a total 
of 26 also participated in the 2000 survey. Another 6 coun-
tries answered the 2000 survey only, whereas still another 7 
countries answered the 2017 survey only.
As in the earlier survey, there were large variations across 
Europe—somewhat less in EU countries—concerning the 
number of physicians and specialists per million inhabitants. 
For certain specialties (neurology, clinical neurophysiology, 
pediatrics, psychiatry, and internal medicine) the ranges were 
larger, with higher maximal numbers in non- EU countries 
(Table 2).
F I G U R E  1  The map shows the regional density of multidisciplinary epilepsy teams without (A) and with (B) surgical programs in the 
responding European Union (EU) countries. Hatched countries on the maps represent nonresponding EU countries; white countries are not member 
states in the EU
150 |   ZELANO Et AL.
Positive changes include higher numbers of physicians 
involved in epilepsy care, especially neurologists and pedi-
atricians, but also to some extent pediatric neurologists. The 
reported total number of physicians per million inhabitants in 
Europe has increased since the 2000 inventory. The increased 
availability of neurologists may be reflected in the diminished 
gap between the best- and the least- provided areas with re-
gard to the competence of the providers, as seen in Table 4. 
The majority of adults with epilepsy are reported to be often 
treated by neurologists both in the best- (97%) and least- 
provided areas (93%) as compared to the 2000 survey where 
the proportions were 88% and 47%. Persons with learning dis-
orders are also more commonly treated by neurologists today: 
81% in the best- provided vs 60% in the least- provided areas, 
compared to 53% and 34% in the 2000 survey. Although the 
numbers show an improvement, the findings nonetheless 
demonstrate a remaining gap in the care provided to persons 
with learning disabilities, who remain a relatively neglected 
group. This observation is in agreement with a recent national 
survey on the care of this patient group.3 Treatment of the 
epilepsy aside, neurologists are often paramount in ensuring 
that epilepsy does not hamper adequate attention to somatic 
or psychiatric/neuropsychiatric comorbidities, family sup-
port, and meaningful occupation. Children with epilepsy were 
often treated by pediatric neurologists in the best- provided 
areas, but this was not the case in the least- provided areas in 
many chapters, indicating substantial room for improvement.
There also seems to be some regional catch- up in the pro-
vision of epilepsy care. Although differences between the 
regions still exist, for instance, regarding the availability of 
AEDs, a finding in agreement with another recent report,4 
regional differences seem less evident than in the last survey, 
especially within the EU. For countries within the EU, the 
high cost of AEDs did not seem to be the most important 
problem and was reported as such by only 1 of 23 (4%) EU 
chapters, in contrast to the whole group, from which 4 of 33 
chapters considered this an important problem (12%).
However, although the reported total number of physicians 
has increased, the density of epilepsy teams—with or without 
surgery programs—has not changed to any greater degree. At 
least one chapter in each region reported total absence of multi-
disciplinary teams without a surgical program. The lack of such 
comprehensive teams indicates that people with epilepsy do 
not obtain the services needed to optimize treatment, consider 
comorbidity, and give necessary psychosocial support.5 In ad-
dition, use of epilepsy specialist nurses and nurse practitioners 
may constitute cost- effective ways of providing epilepsy care.6,7
In all regions outside the Western group, some chapters 
also reported total absence of epilepsy surgery programs, 
which highlights the need for international collaboration 
in the management of medically refractory patients. Cross- 
border cooperation is a commitment from the EU commis-
sion within the frame of the European Reference Networks 
(https://www.eurordis.org/content/about-european-refer-
ence-networks), which include EpiCARE, the European 
Reference Network for Complex and Rare Epilepsies.
The lack of multidisciplinary epilepsy teams and the qual-
itative reports from several chapters of a lack of epilepsy spe-
cialists are the most important obstacles to providing basic 
epilepsy care. This finding indicates that the increased number 
of neurologists has not been paralleled by an increase in the 
resources devoted to epilepsy care, despite epilepsy being the 
most common chronic neurologic disorder. This situation con-
trasts with several commitments from policymakers, for ex-
ample, the European Written Declaration on Epilepsy, which 
was adopted by the EU parliament in 2011 and which calls on 
the European Commission and European Council to prioritize 
epilepsy as a major disease that imposes a significant burden 
across Europe (https://www.epilepsy.org.uk/news/news/euro-
pean-written-declaration-epilepsy-adopted-european-parli-
ament). Providing adequate resources for epilepsy care is a 
national responsibility, and our findings should spur efforts 
from policymakers to this effect. One possible measure could 
be national guidelines stipulating lowest acceptable level of 
care. Another important area is further studies on how to in-
crease access to care in the least- provided areas.
The strengths of this study include that the chapter rep-
resentatives answering the survey probably are those most 
updated on the provision of basic epilepsy care in their 
countries. In addition, because this was a repeat survey, it 
offered some possibilities for comparison with the situation 
in Europe in 2000 when the first survey was performed. The 
weaknesses include lower response rate than the first survey, 
different chapters in the regions participating in each survey, 
and that some of the answers may be assessments not always 
based on published data. The survey was undertaken with 
the aim of providing aggregated regional data, in line with 
the ESBACE objective, whereas developments in individual 
countries are a national responsibility.
In conclusion, there have been some improvements con-
cerning the availability of care for people with epilepsy in 
Europe over the last 17 years, but there are still a number 
of problem areas where there has been little improvement or 
where there are important regional differences.
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